Flecainide Acetate Tablet
NDC Package 62135-660-60
Package Information
Flecainide Acetate tablets is in patients without structural heart disease, flecainide acetate is indicated for the prevention of— paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms— paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate is also indicated for the prevention of— documented ventricular arrhythmias, such as sustainedventricular tachycardia ( sustainedVT), that in the judgment of the physician are life-threatening. This formulation utilizes a tablet delivery system. Marketed by Chartwell Rx, Llc, this product is identified by NDC 62135-660 and is authorized under FDA application ANDA079164.
Identification & Billing
- RxCUI: 886662 - flecainide acetate 50 MG Oral Tablet
- RxCUI: 886666 - flecainide acetate 100 MG Oral Tablet
- RxCUI: 886671 - flecainide acetate 150 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62135 - Chartwell Rx, Llc
- 62135-660 - Flecainide Acetate
- 62135-660-60 - 60 TABLET in 1 BOTTLE, GLASS
- 62135-660 - Flecainide Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62135-660-60 identifies a specific commercial package of 60 tablet in 1 bottle, glass of Flecainide Acetate, a human prescription drug labeled by Chartwell Rx, Llc. This tablet is formulated for oral use and contains flecainide acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chartwell Rx, Llc on July 09, 2009. The current certification is valid through December 31, 2027.
How is this Chartwell Rx, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62135066060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.